fluorouracil has been researched along with Deep Vein Thrombosis in 63 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches." | 9.12 | Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007) |
| "Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown." | 8.31 | Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 7.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| " Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment." | 7.81 | Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015) |
| "We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches." | 7.77 | Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 7.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| "In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis." | 7.75 | Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009) |
| "Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| "We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003." | 7.74 | [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007) |
| "We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration." | 7.74 | Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 7.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited." | 6.87 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018) |
| "This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy." | 6.80 | Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)." | 6.77 | Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012) |
| "From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 6.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 5.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
| "Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy." | 5.32 | Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004) |
| "The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 5.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches." | 5.12 | Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007) |
| "Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)." | 5.09 | Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999) |
| "Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown." | 4.31 | Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023) |
| " Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment." | 3.81 | Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 3.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| "We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches." | 3.77 | Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| "We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP)." | 3.76 | [A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi]. ( Doki, Y; Eguchi, H; Hashimoto, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H, 2010) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 3.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| "In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis." | 3.75 | Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009) |
| "We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003." | 3.74 | [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007) |
| "We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration." | 3.74 | Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007) |
| "Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 3.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited." | 2.87 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018) |
| "This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy." | 2.80 | Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)." | 2.77 | Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012) |
| "From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 2.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
| "Unresectable biliary tract cancers have a very poor prognosis." | 2.71 | Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study. ( Cantore, M; Carlone, N; Caudana, R; Fiorentini, G; Mambrini, A; Manni, A; Rabbi, C; Torri, T; Zamagni, D, 2003) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor." | 2.70 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002) |
| "Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis." | 2.70 | [Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis]. ( Ahn, SH; Cheong, JY; Chon, CY; Han, KH; Kim, JS; Lee, DY; Moon, YM; Seong, JS; Youn, YH, 2002) |
| "IORT using the INTRABEAM radiation system combined with portal vein infusion chemotherapy is promising for select patients with PVTT." | 1.56 | INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. ( Han, M; He, Y; Liang, H; Shao, Z; Song, X, 2020) |
| " In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy)." | 1.46 | Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. ( Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Seong, J; Song, JE; Song, K; Won, JY, 2017) |
| "Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%." | 1.43 | Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. ( Choi, GH; Choi, JS; Han, DH; Han, KH; Joo, DJ; Kim, MS; Kim, SI; Park, YN; Seong, J, 2016) |
| "Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port." | 1.39 | Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013) |
| "Capecitabine was given concomitantly at a dose of 600 mg/m2 twice daily during radiotherapy." | 1.39 | Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ, 2013) |
| "Metronomic chemotherapy may be a safe and useful palliative treatment in HCC patients with major PVT." | 1.38 | Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. ( Bae, SH; Cha, JH; Choi, BG; Choi, JY; Chun, HJ; Jang, JW; Kim, HL; Woo, HY; Yoon, SK; Youn, JM, 2012) |
| "The prognosis for hepatocellular carcinoma (HCC) along with portal vein tumor thrombi (PVTT) is poor, and surgery has not been considered an option." | 1.38 | Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. ( Liu, B; Liu, J; Ou, Q; Wang, Y; Zhang, D, 2012) |
| "We performed an operation for cancer of the rectum." | 1.36 | [Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer]. ( Hosokawa, T; Iwao, Y; Koshiishi, H; Koshinaga, T; Matsuyama, T; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H, 2010) |
| "These patients can also be affected by superior vena cava syndrome causing dyspnea followed by trunk or extremity swelling." | 1.35 | Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation. ( Kickuth, R; Sauter, A; Schmidt, F; Triller, J, 2008) |
| "The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)." | 1.33 | Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005) |
| "Colorectal cancer patients with central venous catheters (CVC) for pharmacokinetic modulating chemotherapy (PMC) have a substantial risk of venous thromboembolism (VTE)." | 1.33 | Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. ( Fujiwara, Y; Gega, M; Hashimoto-Tamaoki, T; Higasa, S; Ikeuchi, H; Inoue, T; Nakano, H; Noda, M; Oshima, T; Sakaki, T; Shoji, Y; Tsukamoto, K; Yamamura, T; Yanagi, H; Yoshikawa, R, 2005) |
| "The prognosis of hepatocellular carcinoma (HCC) with tumor thrombosis of the main trunk or major branches of the portal vein (mPVTT) is extremely poor, even if it is curatively resected." | 1.33 | Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. ( Mimura, T; Niguma, T; Tutui, N, 2005) |
| "To estimate the risk of venous thrombosis associated with pancreatic malignancies we followed a cohort of patients with pancreatic cancer (n = 202)." | 1.33 | High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. ( Blom, JW; Osanto, S; Rosendaal, FR, 2006) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 1.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
| "Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy." | 1.32 | Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004) |
| "Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis, and the development of new therapeutic strategies is necessary." | 1.31 | Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. ( Kaneko, S; Kobayashi, K; Urabe, T, 2002) |
| "The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 1.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 29 (46.03) | 29.6817 |
| 2010's | 28 (44.44) | 24.3611 |
| 2020's | 4 (6.35) | 2.80 |
| Authors | Studies |
|---|---|
| Narita, H | 1 |
| Kawaratani, H | 1 |
| Shibamoto, A | 1 |
| Takeda, S | 1 |
| Ozutsumi, T | 1 |
| Tsuji, Y | 1 |
| Fujinaga, Y | 1 |
| Kitagawa, K | 1 |
| Nishimura, N | 1 |
| Hokuto, D | 1 |
| Sho, M | 1 |
| Yoshiji, H | 1 |
| Fu, Y | 1 |
| Peng, W | 1 |
| Zhang, W | 1 |
| Yang, Z | 1 |
| Hu, Z | 1 |
| Pang, Y | 1 |
| Hu, D | 1 |
| Chen, J | 1 |
| Wang, J | 1 |
| Zhou, Z | 1 |
| Xu, L | 1 |
| Chen, M | 1 |
| Zhang, Y | 1 |
| Ding, Y | 1 |
| Wang, S | 1 |
| Qiu, Z | 1 |
| Zhu, C | 1 |
| Wang, Y | 2 |
| Zhao, S | 1 |
| Qiu, W | 1 |
| Wang, K | 1 |
| Lv, J | 1 |
| Qi, W | 1 |
| Nakamura, M | 3 |
| Ishigure, K | 1 |
| Watanabe, T | 1 |
| Mashita, N | 1 |
| Tobinaga, J | 1 |
| Fukuyama, R | 1 |
| Song, X | 1 |
| He, Y | 1 |
| Liang, H | 1 |
| Han, M | 1 |
| Shao, Z | 1 |
| Song, JE | 1 |
| Jung, KS | 1 |
| Kim, DY | 3 |
| Song, K | 1 |
| Won, JY | 1 |
| Lee, HW | 1 |
| Kim, BK | 1 |
| Kim, SU | 3 |
| Park, JY | 4 |
| Ahn, SH | 3 |
| Seong, J | 3 |
| Han, KH | 4 |
| Greally, M | 1 |
| Pilson, K | 1 |
| Linehan, A | 1 |
| O'Keane, C | 1 |
| Shields, CJ | 1 |
| Conneely, JB | 1 |
| McCaffrey, JA | 1 |
| Choi, JH | 1 |
| Chung, WJ | 2 |
| Bae, SH | 5 |
| Song, DS | 3 |
| Song, MJ | 3 |
| Kim, YS | 2 |
| Yim, HJ | 2 |
| Jung, YK | 1 |
| Suh, SJ | 1 |
| Cho, SB | 2 |
| Khanna, A | 1 |
| Reece-Smith, AM | 1 |
| Cunnell, M | 1 |
| Madhusudan, S | 1 |
| Thomas, A | 1 |
| Bowrey, DJ | 1 |
| Parsons, SL | 1 |
| Furuyama, H | 1 |
| Fuji, H | 1 |
| Okumura, S | 1 |
| Nishigori, T | 1 |
| Kadokawa, Y | 1 |
| Kondo, M | 3 |
| Machimoto, T | 1 |
| Asao, Y | 1 |
| Yoshimura, T | 1 |
| Lee, SW | 1 |
| Kim, HY | 1 |
| Lee, YJ | 2 |
| Oh, JS | 1 |
| Chun, HJ | 3 |
| Lee, HG | 1 |
| Choi, JY | 3 |
| Yoon, SK | 3 |
| Olgun, DC | 1 |
| Bakan, S | 1 |
| Samanci, C | 1 |
| Tutar, O | 1 |
| Demiryas, S | 1 |
| Korkmazer, B | 1 |
| Kantarci, F | 1 |
| Muñoz Martín, AJ | 1 |
| García Alfonso, P | 1 |
| Rupérez Blanco, AB | 1 |
| Pérez Ramírez, S | 1 |
| Blanco Codesido, M | 1 |
| Martín Jiménez, M | 1 |
| Jang, JY | 1 |
| Lee, SH | 1 |
| Park, SY | 1 |
| Yang, JM | 1 |
| Wu, J | 1 |
| Huang, WJ | 1 |
| Wang, HY | 1 |
| Wang, YF | 1 |
| Peng, BG | 2 |
| Zhou, Q | 2 |
| Al-Hameed, FM | 1 |
| Nagamatsu, H | 2 |
| Sumie, S | 3 |
| Niizeki, T | 1 |
| Tajiri, N | 1 |
| Iwamoto, H | 2 |
| Aino, H | 1 |
| Nakano, M | 1 |
| Shimose, S | 1 |
| Satani, M | 1 |
| Okamura, S | 1 |
| Kuromatsu, R | 2 |
| Matsugaki, S | 1 |
| Kurogi, J | 1 |
| Kajiwara, M | 1 |
| Koga, H | 1 |
| Torimura, T | 2 |
| Han, DH | 1 |
| Joo, DJ | 1 |
| Kim, MS | 2 |
| Choi, GH | 1 |
| Choi, JS | 1 |
| Park, YN | 1 |
| Kim, SI | 1 |
| Redana, S | 1 |
| Sharp, A | 1 |
| Lote, H | 1 |
| Mohammed, K | 1 |
| Papadimitraki, E | 1 |
| Capelan, M | 1 |
| Ring, A | 1 |
| Akiyama, M | 1 |
| Miyaaki, H | 1 |
| Miuma, S | 1 |
| Shibata, H | 1 |
| Fujimoto, M | 1 |
| Takeshita, S | 1 |
| Ozawa, E | 1 |
| Ichikawa, T | 1 |
| Nakao, K | 1 |
| Eguchi, K | 1 |
| Fernández Sarabia, MT | 1 |
| Rodríguez García, JM | 1 |
| Cardenal Escarcena, A | 1 |
| Serrano Vicente, J | 1 |
| García Bernardo, L | 1 |
| Sun, B | 1 |
| Luo, M | 1 |
| Lu, Z | 1 |
| Meng, Y | 1 |
| Wu, S | 1 |
| Wu, M | 1 |
| Eun, JR | 1 |
| Lee, HJ | 1 |
| Moon, HJ | 1 |
| Kim, TN | 1 |
| Kim, JW | 1 |
| Chang, JC | 1 |
| Katamura, Y | 1 |
| Aikata, H | 2 |
| Kimura, Y | 1 |
| Kawaoka, T | 2 |
| Takaki, S | 2 |
| Waki, K | 1 |
| Hiramatsu, A | 1 |
| Kawakami, Y | 1 |
| Takahashi, S | 2 |
| Ishikawa, M | 1 |
| Hieda, M | 1 |
| Kakizawa, H | 1 |
| Chayama, K | 2 |
| Hirooka, M | 1 |
| Koizumi, Y | 1 |
| Kisaka, Y | 1 |
| Abe, M | 1 |
| Murakami, H | 1 |
| Matsuura, B | 1 |
| Hiasa, Y | 1 |
| Onji, M | 1 |
| Hiraki, M | 1 |
| Mizukami, N | 1 |
| Yoshida, H | 1 |
| Sata, M | 2 |
| Hosokawa, T | 1 |
| Tokita, H | 1 |
| Matsuyama, T | 1 |
| Sakamoto, K | 1 |
| Nishida, K | 1 |
| Iwao, Y | 1 |
| Koshiishi, H | 1 |
| Okamura, T | 1 |
| Koshinaga, T | 1 |
| Hashimoto, Y | 1 |
| Wada, H | 5 |
| Kobayashi, S | 2 |
| Marubashi, S | 4 |
| Eguchi, H | 3 |
| Takeda, Y | 2 |
| Tanemura, M | 2 |
| Umeshita, K | 6 |
| Doki, Y | 2 |
| Mori, M | 2 |
| Nagano, H | 6 |
| Tomimaru, Y | 1 |
| Osuga, K | 1 |
| Kasai, K | 1 |
| Ushio, A | 1 |
| Kasai, Y | 1 |
| Sawara, K | 1 |
| Miyamoto, Y | 1 |
| Oikawa, K | 1 |
| Kuroda, H | 1 |
| Takikawa, Y | 1 |
| Suzuki, K | 1 |
| Liu, J | 1 |
| Zhang, D | 1 |
| Liu, B | 1 |
| Ou, Q | 1 |
| Woo, HY | 1 |
| Youn, JM | 1 |
| Jang, JW | 3 |
| Cha, JH | 1 |
| Kim, HL | 1 |
| Choi, BG | 2 |
| Park, MS | 1 |
| Chon, CY | 2 |
| Kim, JY | 1 |
| Yoo, EJ | 1 |
| Kwon, JH | 1 |
| Kim, KJ | 1 |
| Kay, CS | 1 |
| Ducreux, M | 1 |
| Adenis, A | 1 |
| Pignon, JP | 1 |
| François, E | 1 |
| Chauffert, B | 1 |
| Ichanté, JL | 1 |
| Boucher, E | 1 |
| Ychou, M | 1 |
| Pierga, JY | 1 |
| Montoto-Grillot, C | 1 |
| Conroy, T | 1 |
| Ando, E | 1 |
| Tanaka, M | 1 |
| Yamashita, F | 1 |
| Yutani, S | 1 |
| Fukumori, K | 1 |
| Yano, Y | 1 |
| Okuda, K | 1 |
| Mainwaring, CJ | 1 |
| Naylor, E | 1 |
| Jerwood, S | 1 |
| Hall, V | 1 |
| Page, A | 1 |
| James, CM | 1 |
| Kim, JS | 2 |
| Lee, DY | 1 |
| Seong, JS | 1 |
| Youn, YH | 1 |
| Cheong, JY | 2 |
| Moon, YM | 1 |
| Videtic, GM | 1 |
| Campbell, C | 1 |
| Vincent, MD | 1 |
| Lai, YC | 1 |
| Shih, CY | 1 |
| Jeng, CM | 1 |
| Yang, SS | 1 |
| Hu, JT | 1 |
| Sung, YC | 1 |
| Liu, HT | 1 |
| Hou, SM | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Tham, J | 1 |
| Albertsson, M | 1 |
| Cantore, M | 2 |
| Mambrini, A | 2 |
| Fiorentini, G | 2 |
| Rabbi, C | 2 |
| Zamagni, D | 2 |
| Caudana, R | 2 |
| Pennucci, C | 1 |
| Sanguinetti, F | 1 |
| Lombardi, M | 1 |
| Nicoli, N | 1 |
| Yoshikawa, R | 1 |
| Yanagi, H | 1 |
| Noda, M | 1 |
| Ikeuchi, H | 1 |
| Nakano, H | 1 |
| Gega, M | 1 |
| Tsukamoto, K | 1 |
| Oshima, T | 1 |
| Inoue, T | 1 |
| Fujiwara, Y | 1 |
| Shoji, Y | 1 |
| Sakaki, T | 1 |
| Higasa, S | 1 |
| Hashimoto-Tamaoki, T | 1 |
| Yamamura, T | 1 |
| Niguma, T | 1 |
| Mimura, T | 1 |
| Tutui, N | 1 |
| Ota, H | 3 |
| Sakon, M | 4 |
| Yamamoto, T | 2 |
| Damdinsuren, B | 2 |
| Miyamoto, A | 2 |
| Dono, K | 4 |
| Nakamori, S | 3 |
| Wakasa, K | 2 |
| Monden, M | 4 |
| Blom, JW | 1 |
| Osanto, S | 1 |
| Rosendaal, FR | 1 |
| Lim, TY | 1 |
| Cho, SW | 1 |
| Sim, SJ | 1 |
| Choi, SJ | 1 |
| Choi, JW | 1 |
| Kwon, HC | 1 |
| Lee, KM | 1 |
| Kim, JK | 1 |
| Won, JH | 1 |
| Yoo, BM | 1 |
| Lee, KJ | 1 |
| Hahm, KB | 1 |
| Kim, JH | 1 |
| Oh, HJ | 1 |
| Lee, SY | 1 |
| Kim, CW | 1 |
| Chang, UI | 1 |
| Nam, SW | 1 |
| Cha, SB | 1 |
| Byun, JY | 1 |
| Carlone, N | 1 |
| Manni, A | 1 |
| Torri, T | 1 |
| Donadon, M | 1 |
| Vauthey, JN | 1 |
| Loyer, EM | 1 |
| Charnsangavej, C | 1 |
| Abdalla, EK | 1 |
| Imai, Y | 2 |
| Fukuda, K | 1 |
| Matsumoto, H | 1 |
| Noda, T | 1 |
| Naganuma, A | 1 |
| Toyoda, M | 1 |
| Hamada, T | 1 |
| Hagiwara, S | 1 |
| Yanagisawa, M | 1 |
| Kosone, T | 1 |
| Arai, H | 1 |
| Abe, T | 1 |
| Takagi, H | 1 |
| Sauter, A | 1 |
| Triller, J | 1 |
| Schmidt, F | 1 |
| Kickuth, R | 1 |
| Ishikawa, T | 1 |
| Imai, M | 1 |
| Kamimura, H | 1 |
| Tsuchiya, A | 1 |
| Togashi, T | 1 |
| Watanabe, K | 1 |
| Seki, K | 1 |
| Ohta, H | 1 |
| Yoshida, T | 1 |
| Kamimura, T | 1 |
| Uka, K | 1 |
| Miki, D | 1 |
| Jeong, SC | 1 |
| Toyota, N | 1 |
| Ito, K | 1 |
| Liang, LJ | 1 |
| Hu, WJ | 1 |
| Yin, XY | 1 |
| Li, DM | 1 |
| Lu, MD | 1 |
| Martenson, JA | 1 |
| Shanahan, TG | 1 |
| O'Connell, MJ | 1 |
| Cobau, CD | 1 |
| Schroeder, G | 1 |
| Burch, PA | 1 |
| Levitt, R | 1 |
| Rowland, KM | 1 |
| Orlando, L | 1 |
| Colleoni, M | 1 |
| Nolè, F | 1 |
| Biffi, R | 1 |
| Rocca, A | 1 |
| Curigliano, G | 1 |
| Ferretti, G | 1 |
| Peruzzotti, G | 1 |
| de Braud, F | 1 |
| Masci, G | 1 |
| Goldhirsch, A | 1 |
| Schaefer, U | 1 |
| Micke, O | 1 |
| Schueller, P | 1 |
| Willich, N | 1 |
| Meropol, NJ | 1 |
| Rustum, YM | 1 |
| Creaven, PJ | 1 |
| Blumenson, LE | 1 |
| Frank, C | 1 |
| Kaneko, S | 1 |
| Urabe, T | 1 |
| Kobayashi, K | 1 |
| Yamada, A | 1 |
| Kawata, S | 1 |
| Iijima, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949] | Phase 1/Phase 2 | 39 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2021-07-01 | Enrolling by invitation | ||
| International Registry on Cholangiocarcinoma Treatment[NCT01920503] | 40 participants (Anticipated) | Observational [Patient Registry] | 2013-07-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Deep Vein Thrombosis
| Article | Year |
|---|---|
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Death; Cisplatin; Fluorouracil; Humans; Immunotherapy; Liver Neoplas | 2023 |
16 trials available for fluorouracil and Deep Vein Thrombosis
| Article | Year |
|---|---|
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cat | 2018 |
Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 2015 |
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cispl | 2016 |
Clinical studies of laser ablation in treatment of primary liver carcinoma-associated portal vein tumor thrombus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2010 |
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2012 |
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2002 |
[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Fluo | 2002 |
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Fluoro | 2003 |
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2007 |
Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary | 2003 |
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2007 |
Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2007 |
Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Modality | 1999 |
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr | 1999 |
46 other studies available for fluorouracil and Deep Vein Thrombosis
| Article | Year |
|---|---|
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Port | 2022 |
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Ind | 2023 |
[A Case of FOLFOXIRI plus BV Therapy Responding to Liver Metastasis of Rectal Cancer with the Portal Venous Tumor Thrombi(Vp4)as Oncologic Emergency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatectom | 2019 |
INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2020 |
Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellu | 2017 |
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein.
Topics: Adenocarcinoma, Mucinous; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2019 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
[A case of recurrent colon cancer developed thrombosis in superior mesenteric vein after chemotherapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2013 |
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chi-Square D | 2013 |
Simultaneous thrombosis of superior mesenteric artery and superior mesenteric vein following chemotherapy: MDCT findings.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; | 2014 |
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2015 |
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
Topics: Adult; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluor | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2016 |
Significance of trans-hepatic arterial chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2008 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2008 |
Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2009 |
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2010 |
Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Combin | 2010 |
Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cause of Death; Cis | 2010 |
[Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer].
Topics: Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antin | 2010 |
[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci | 2011 |
Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit Analy | 2012 |
Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
Topics: Administration, Metronomic; Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepat | 2012 |
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiothe | 2013 |
Superior venocaval obstruction secondary to central venous catheter-related thromboses in two patients with metastatic colorectal carcinoma receiving weekly 5-flurouracil. Should adjusted-dose warfarin be used as thromboprophylaxis?
Topics: Aged; Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Colorectal Neoplasms; | 2002 |
Primary chemoradiation as definitive treatment for unresectable cancer of the trachea.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2003 |
Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola | 2005 |
Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy.
Topics: Adult; Aged; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Catheterization | 2005 |
Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2005 |
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Prog | 2005 |
High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.
Topics: Antimetabolites, Antineoplastic; Cohort Studies; Female; Fibrinolytic Agents; Fluorouracil; Humans; | 2006 |
[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2006 |
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Hepatectomy | 2007 |
[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2007 |
Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization, Peripheral; Colorectal Neoplasms; C | 2008 |
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cohort Studi | 2007 |
Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2008 |
Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2000 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2002 |
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 2002 |